| Literature DB >> 19005461 |
C Sachse-Seeboth1, J Pfeil, D Sehrt, I Meineke, M Tzvetkov, E Bruns, W Poser, S V Vormfelde, J Brockmöller.
Abstract
The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9*2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes. CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19005461 DOI： 10.1038/clpt.2008.213
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875